MX2020003662A - Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona. - Google Patents

Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona.

Info

Publication number
MX2020003662A
MX2020003662A MX2020003662A MX2020003662A MX2020003662A MX 2020003662 A MX2020003662 A MX 2020003662A MX 2020003662 A MX2020003662 A MX 2020003662A MX 2020003662 A MX2020003662 A MX 2020003662A MX 2020003662 A MX2020003662 A MX 2020003662A
Authority
MX
Mexico
Prior art keywords
guanfacine
transdermal
therapeutic system
hybrid polymer
acrylic hybrid
Prior art date
Application number
MX2020003662A
Other languages
English (en)
Inventor
Marco Emgenbroich
Eva - Marie Prinz
Elke Klein
Heike Kluth
Xavier Thomas
Linda Sue Nartker
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of MX2020003662A publication Critical patent/MX2020003662A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un sistema terapéutico transdérmico para la administración transdérmica de guanfacina, que comprende una estructura de capa que contiene guanfacina, dicha estructura de capa que contiene guanfacina comprende: A) una capa de refuerzo; y B) una capa que contiene guanfacina en donde el sistema terapéutico transdérmico comprende al menos un polímero híbrido acrílico de silicona.
MX2020003662A 2017-10-11 2018-10-11 Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona. MX2020003662A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570748P 2017-10-11 2017-10-11
EP17205538 2017-12-05
PCT/EP2018/077790 WO2019072996A1 (en) 2017-10-11 2018-10-11 TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL GUANFACIN ADMINISTRATION COMPRISING A SILICONE-ACRYLIC HYBRID POLYMER

Publications (1)

Publication Number Publication Date
MX2020003662A true MX2020003662A (es) 2020-10-01

Family

ID=63878659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003662A MX2020003662A (es) 2017-10-11 2018-10-11 Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona.

Country Status (13)

Country Link
US (1) US12048770B2 (es)
EP (1) EP3694497B1 (es)
JP (2) JP2020536878A (es)
KR (1) KR102734235B1 (es)
CN (1) CN111491621A (es)
AU (1) AU2018348769A1 (es)
BR (1) BR112020007093A2 (es)
CA (1) CA3079694A1 (es)
ES (1) ES2954714T3 (es)
MX (1) MX2020003662A (es)
RU (1) RU2020115559A (es)
TW (1) TW201924663A (es)
WO (1) WO2019072996A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079694A1 (en) 2017-10-11 2019-04-18 Dow Silicones Corporation Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer
AU2018348801B2 (en) 2017-10-11 2024-06-27 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer
CN111447926B (zh) 2017-10-11 2024-04-30 罗曼治疗系统股份公司 用于透皮施用胍法辛的包含至少一种添加剂的透皮治疗系统
CN113648285B (zh) * 2021-07-15 2022-11-11 南京海纳医药科技股份有限公司 一种盐酸胍法辛膜控释片剂及其制备方法
EP4395749B1 (en) * 2021-08-30 2025-11-19 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid
DE102021128911A1 (de) * 2021-11-05 2023-05-11 Lts Lohmann Therapie-Systeme Ag. Diclofenac enthaltendes tts mit dimethylpropylenharnstoff

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
JPH01265021A (ja) 1987-10-29 1989-10-23 Hercon Lab Corp 薬理学的活性物質を含有する組成物を動物組織に制御放出および供給するための物品
US5028431A (en) * 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
JPH07145048A (ja) 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 医療用貼付剤
US5843472A (en) 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
CN100411692C (zh) 2004-01-13 2008-08-20 北京康倍得医药技术开发有限公司 丙烯酸基粘合剂组合物及其药物组合物和透皮治疗系统
GT200600396A (es) 2005-09-07 2007-04-23 Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales
JP2007284370A (ja) 2006-04-14 2007-11-01 Alcare Co Ltd 体表面用貼付材
US8569416B2 (en) 2006-06-06 2013-10-29 Dow Corning Corporation Single phase silicone acrylate formulation
EP2024406B1 (en) * 2006-06-06 2012-08-01 Dow Corning Corporation A silicone acrylate hybrid composition
BRPI1014886B1 (pt) * 2009-04-24 2020-02-11 Henkel IP & Holding GmbH Polímeros acrílicos de silicone híbridos, seus métodos de preparação, adesivos e soluções de uma composição adesiva sensível à pressão compreendendo os mesmos.
WO2012014589A1 (ja) 2010-07-29 2012-02-02 久光製薬株式会社 医療用貼付剤
US9080030B2 (en) 2010-09-14 2015-07-14 Lorama Group International Inc. Low VOC and APE free universal paint colourant compositions
EP2584016A1 (en) 2011-10-21 2013-04-24 Dow Corning Corporation Single phase silicone acrylate formulation
JP2013139554A (ja) * 2011-11-29 2013-07-18 Dow Corning Corp シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法
CA2896055C (en) * 2012-12-28 2021-02-16 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine and clonidine
AU2015296807A1 (en) * 2014-07-31 2017-03-09 Noven Pharmaceuticals, Inc. Silicone-containing acrylic polymers for transdermal drug delivery compositions
US10316228B2 (en) 2015-02-09 2019-06-11 Dow Silicones Corporation Multi-phase silicone acrylic hybrid visco-elastic compositions and methods of making same
EP3349737A4 (en) 2015-09-14 2019-05-15 Amneal Pharmaceuticals LLC SYSTEM FOR TRANSDERING
CN111447926B (zh) 2017-10-11 2024-04-30 罗曼治疗系统股份公司 用于透皮施用胍法辛的包含至少一种添加剂的透皮治疗系统
CA3079694A1 (en) 2017-10-11 2019-04-18 Dow Silicones Corporation Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer
AU2018348801B2 (en) 2017-10-11 2024-06-27 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer
EP3764996A1 (en) 2018-03-13 2021-01-20 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system comprising a silicone acrylic hybrid polymer

Also Published As

Publication number Publication date
EP3694497A1 (en) 2020-08-19
CN111491621A (zh) 2020-08-04
CA3079694A1 (en) 2019-04-18
ES2954714T3 (es) 2023-11-23
KR102734235B1 (ko) 2024-11-27
TW201924663A (zh) 2019-07-01
EP3694497B1 (en) 2023-06-07
JP2020536878A (ja) 2020-12-17
JP7659589B2 (ja) 2025-04-09
KR20200070307A (ko) 2020-06-17
WO2019072996A1 (en) 2019-04-18
JP2023116688A (ja) 2023-08-22
EP3694497C0 (en) 2023-06-07
AU2018348769A1 (en) 2020-04-16
RU2020115559A (ru) 2021-11-12
US20200397714A1 (en) 2020-12-24
US12048770B2 (en) 2024-07-30
BR112020007093A2 (pt) 2020-09-24

Similar Documents

Publication Publication Date Title
MX2020003662A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona.
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
MX2020003667A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona.
MX2016010554A (es) Sistema y metodo para la colocacion de un implante de anuloplastia.
MX2017014806A (es) Conjugados oligonucleotido- peptido.
MX2015012576A (es) Composiciones a base de nanoparticulas.
MX2020011371A (es) Nuevos dispositivos medicos, vehiculos de suministro y fabricacion de los mismos.
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
MX2019005325A (es) Matriz para el crecimiento de celulas.
SV2016005214A (es) Sistema de administración farmacológico
ECSP15040888A (es) PROTEÍNAS DE UNIÓN ESPECÍFICAS DUALES DIRIGIDAS CONTRA TNF alfa
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
CR20150647A (es) Sistema de liberación transdérmica
MX393610B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
BR112014024494A2 (pt) dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
BR112017005361A2 (pt) emplastro de opipramol
CU20150018A7 (es) Composición para el tratamiento de la infección por hepatitis b o coinfección por hepatitis b/hepatitis d
BR112013024585A8 (pt) formas de dosagem farmacêutica de liberação controlada
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
BR112016012615A8 (pt) sistemas, e kit
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
AR090738A1 (es) Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3